| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.2 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.2 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |